Helius Medical Technologies (HSDT) Soars 19.35% on CignaHealth Authorization

Generado por agente de IAAinvest Pre-Market Radar
miércoles, 18 de junio de 2025, 4:29 am ET1 min de lectura
HSDT--

On June 18, 2025, Helius MedicalHSDT-- Technologies, Inc. (HSDT) saw a significant surge in its stock price, rising by 19.35% in pre-market trading.

Helius Medical Technologies, Inc. has recently secured another major milestone in its efforts to expand the adoption of its PoNS Device. CignaHealth has become the fifth major payer to authorize claims for payment for the PoNS Device, following the recent authorization by Anthem MultiPlan. This development is a critical step towards wider adoption of the technology, as it boosts patient access and potential revenue.

This authorization is likely to have a positive impact on Helius Medical's share price, as it enhances the device's market reach and financial viability. The company's strides in gaining insurance reimbursement for the PoNS Device are expected to drive further growth and adoption in the healthcare sector.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios